The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
January 2020
in “
British Journal of Dermatology
”
Research cited in this study
9 / 9 results
research Rethinking The Classification Of Alopecia Areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata
The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
research Factors Associated with Severity of Alopecia Areata
The study analyzed factors associated with the severity of alopecia areata in Korean patients, representing the largest case analysis of its kind at the time. It highlighted the need for further research into clinical profiles stratified by disease severity to better understand the condition.
research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Current Treatment of Alopecia Areata
There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
Related Research
1 / 1 results
research Serum Zinc Concentration in Patients With Alopecia Areata
People with severe hair loss have lower zinc levels in their blood.